clinical trial · NCT07123662
γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant
Guangzhou Bio-gene Technology Co., Ltd·early phase1·not yet recruiting·n = 8
LeukemiaMyeloidAcuteGamma-Delta T cell injectionStandard prophylactic treatment
brief summary
This is a prospective, double-arm, single-center, randomized controlled single-blind clinical study
started
Sep 1, 2025
primary completion
May 30, 2028
completion
May 30, 2028
last updated
Aug 14, 2025
detailed description
This study is a prospective, single-center, two-arm, single-blind randomized controlled clinical trial to evaluate the safety and efficacy of γδ T cell infusion in preventing recurrence in patients with high-risk AML after allogeneic transplantation.
official title
A Clinical Study on the Safety and Efficacy of γδ T Cells in Preventing Relapse After Allogeneic Transplantation in High-risk Acute Myeloid Leukemia Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol